同和药业(300636) - 2025 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2025 reached ¥208,819,135.87, an increase of 11.14% year-over-year[5] - Net profit attributable to shareholders decreased by 3.84% to ¥25,178,078.47 in Q3 2025[5] - Net profit after deducting non-recurring gains and losses fell by 11.49% to ¥22,601,594.83 for the quarter[5] - Basic earnings per share for Q3 2025 were ¥0.0599, down 4.01% compared to the same period last year[5] - Total operating revenue for the current period reached ¥636,241,288.48, an increase of 11.6% compared to ¥569,933,408.38 in the previous period[18] - Net profit for the current period was ¥83,664,591.04, a decrease of 12.6% from ¥95,736,461.60 in the previous period[20] - Basic and diluted earnings per share decreased to ¥0.1992 from ¥0.2280, reflecting a decline of 12.5%[20] Assets and Liabilities - Total assets as of September 30, 2025, were ¥3,258,351,204.58, a decrease of 1.84% from the end of the previous year[5] - The total assets decreased to ¥3,258,351,204.58 from ¥3,319,551,672.71, a decline of approximately 1.8%[16] - The total liabilities decreased to ¥882,543,399.26 from ¥1,010,803,786.88, a reduction of about 12.7%[16] - The company's fixed assets decreased to ¥1,201,567,362.67 from ¥1,301,979,988.18, reflecting a decline of approximately 7.7%[16] - The company’s long-term borrowings decreased to ¥190,100,762.13 from ¥398,500,000.00, a reduction of approximately 52.3%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥193,181,615.14, an increase of 19.13%[5] - Net cash flow from operating activities increased by 19.13% to approximately ¥193.18 million, mainly due to increased cash receipts from sales and services[10] - Cash inflow from investment activities was ¥467,217,368.12, significantly higher than ¥60,297,427.00 in the previous period[20] - Net cash flow from investing activities increased by 106.86% to approximately ¥31.64 million, primarily due to increased phase investment in the second phase of the factory project[10] - Cash inflow from financing activities totaled $358,014,762.13, while cash outflow was $507,117,084.41, resulting in a net cash flow of -$149,102,322.28[21] - The ending balance of cash and cash equivalents increased to $242,538,343.08, compared to $116,345,276.10 in the previous period[21] - The company’s cash and cash equivalents net increase was $77,126,105.32, contrasting with a decrease of $376,457,099.64 in the previous period[21] Investments and Expenses - The company reported a significant increase of 319.60% in long-term equity investments, totaling ¥13,392,121.50, due to additional investments in joint ventures[9] - Research and development expenses increased to ¥41,033,872.63, up from ¥39,204,527.63, indicating a focus on innovation[18] - The company reported a financial asset impairment loss of ¥31,639,391.53, compared to ¥12,375,041.28 in the previous period, highlighting potential challenges[19] - Other income increased by 84.06% to approximately ¥10.29 million, mainly due to an increase in government subsidies[10] - Other income rose to ¥10,290,433.00 from ¥5,590,954.46, reflecting improved operational efficiency[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,461[11] - The largest shareholder, Pang Zhengwei, holds 14.77% of shares, with 4.11 million shares pledged[11] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Fenglong Industrial Co., Ltd., holding 13.22%[11] - The total number of restricted shares at the end of the period is 52,593,811, a decrease of 1,575,855 from the beginning of the period[12] Operational Developments - The company completed the expansion project in the second factory area, with some workshops starting equipment debugging during the reporting period[13] - The company has initiated a new project in the second factory area, with construction starting in July 2022[13] Inventory and Receivables - The company’s inventory decreased to ¥533,227,327.70 from ¥552,510,646.85, a decrease of about 3.5%[15] - Accounts receivable rose to ¥118,196,418.18 from ¥94,676,422.41, indicating an increase of about 25%[15] Financial Adjustments - The third quarter financial report was not audited, indicating that the figures may be subject to adjustments[22]